Prime Medicine, Inc. (PRME) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$3.12

From 52W high−53.22%

Volume4.42M

Market cap$565.90M

P/E (TTM)—

P/S (TTM)138.9x

Div yield—

Key dataSep 18, 2026

Open

$3.12

From 52W high

−53.22%

Volume

4.42M

Market cap

$565.90M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.2x

P/E (TTM)

—

RSI (14)

43.2

MomentumView details →

1D Return

−0.64%

YTD Return

−9.94%

SummaryUpdated Jun 1, 2026

Prime Medicine, Inc. (NASDAQ:PRME) is a biotechnology company founded in 2019 and headquartered in Cambridge, Massachusetts. The company went public in October 2022 and focuses on developing genetic therapies using advanced gene editing technology. Prime Medicine represents a next-generation approach to gene editing, building upon the foundation of CRISPR technology to create more precise and versatile genetic modifications for treating various diseases.

Ask drillr about Prime Medicine, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−3.2x

EV/Sales

143.2x

P/S (TTM)

138.9x

P/B (TTM)

14.2x

ProfitabilityView details →

Gross Margin

−1025.61%

Net Margin

−4613.11%

EBITDA Margin

−4431.48%

ROE (TTM)

−471.98%

ROA (TTM)

−75.45%

Asset Turnover

0.01x

GrowthView details →

Revenue YoY

−17.90%

EPS YoY

+31.19%

FCF YoY

−46.59%

Revenue CAGR 3Y

+55.28%

EPS CAGR 3Y

+18.26%

EBITDA YoY

+7.96%

MomentumView details →

1D Return

−0.64%

YTD Return

−9.94%

1Y Return

−36.09%

RSI (14)

43.2

vs 50D SMA

−4.22%

vs 200D SMA

−11.35%

Capital & dividendView details →

Debt/Equity

2.83x

Current Ratio

3.05x

Quick Ratio

3.05x

Div Yield

—

Div Rate

—

Div Growth 1Y

+67.22%

EarningsView details →

EPS (Actual)

−$0.24

EPS Surprise

6.70%

Beats (12Q)

4/12

Next Q EPS Est

−$0.24

Avg Surprise (4Q)

−3.06%

Rev Surprise

−48.74%

Financials snapshotView financials →

Revenue (TTM)

4.07M

Net Income (TTM)

−187.89M

Op. CF (TTM)

−156.05M

Next earningsNov 6, 2026 →

Latest newsMore news →

Prime Medicine, Inc. reported a Q2 2026 loss of $0.24 per share, in line with the Zacks Consensus Estimate, compared to a loss of $0.41 per share a year ago.45d ago

Prime Medicine announced a positive binding resolution of its arbitration with Beam Therapeutics, with the tribunal declaring PM647 within Prime Medicine's field and no monetary damages owed.74d ago

Similar companies

Eupraxia Pharmaceuticals Inc.EPRX Allogene Therapeutics, Inc.ALLO Arvinas, Inc.ARVN Bright Minds Biosciences Inc.DRUG AgomAb Therapeutics N.V. American Depositary SharesAGMB CytomX Therapeutics, Inc.CTMX Find similar companies →

Latest newsMore news →

Prime Medicine, Inc. reported a Q2 2026 loss of $0.24 per share, in line with the Zacks Consensus Estimate, compared to a loss of $0.41 per share a year ago.45d ago Prime Medicine announced a positive binding resolution of its arbitration with Beam Therapeutics, with the tribunal declaring PM647 within Prime Medicine's field and no monetary damages owed.74d ago Prime Medicine received clearance from New Zealand regulators for a clinical trial application for PM577a in H1069Q-mutated Wilson Disease.94d ago